Gland Pharma Limited has officially announced the re-appointment of Ms. Naina Lal Kidwai as an Independent Director. Her second term will span five consecutive years, commencing on May 17, 2026, and concluding on May 16, 2031. This decision, approved by the Board of Directors, remains subject to shareholder approval via postal ballot and e-voting, ensuring continued leadership stability and oversight.
Leadership Continuity
Following a recent board meeting, Gland Pharma Limited has confirmed the decision to extend the tenure of Ms. Naina Lal Kidwai. Having served an initial five-year term since May 17, 2021, Ms. Kidwai will continue her role as an Independent Director for another five-year period, effective May 17, 2026 through May 16, 2031.
Professional Profile
Ms. Kidwai brings extensive industry experience to the Board. Currently serving as the Chairman of Rothschild & Co India, she holds senior advisory positions at Advent Private Equity, TPG Rise Climate, and Lightspeed Venture Partners. Her corporate governance expertise is further evidenced by her directorships on the boards of Holcim, UPL, and Biocon.
Governance and Industry Contributions
An MBA graduate from Harvard Business School and a recipient of the Padma Shri, Ms. Kidwai has a distinguished record of public service and professional leadership. She is a former President of FICCI and has chaired significant regulatory committees, including the SEBI Primary Markets Advisory Committee. Her expertise spans critical areas such as finance, environmental sustainability, and water sanitation policy, providing the company with deep strategic insights.
Next Steps for Formalization
While the Board of Directors has approved the re-appointment, the company will proceed to seek formal approval from its shareholders. This process will be conducted through a postal ballot and e-voting mechanism within the prescribed timelines to finalize the governance transition.
Source: BSE
